கிரீன் வடக்கு அமெரிக்கா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from கிரீன் வடக்கு அமெரிக்கா. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In கிரீன் வடக்கு அமெரிக்கா Today - Breaking & Trending Today

Kyowa Kirin North America Announces Key Executive Appointments in R&D and Medical Affairs As Late-Stage Assets Move Toward Key Milestones

Share this article
Share this article
BEDMINSTER, N.J., May 4, 2021 /PRNewswire/ Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a global specialty pharmaceutical company, recently named Ernesto Aycardi, M.D., to the position of Chief Development Officer on April 26, and is welcoming Eslie Dennis, M.D., MBChB, FCP(SA) in the role of Chief Medical Officer today. These appointments come at a pivotal time for the company, as the North America region aims to realize the full potential of its existing commercial portfolio and compounds being investigated in the pipeline. In particular, the company is working on plans to advance KW-6356, a selective antagonist of adenosine A2A receptors, and KHK4083, an Anti-OX40 Fully Human Antibody, and is also collaborating with partner MEI Pharma to complete the pivotal study and shape a broader development program for zandelisib, a selective PI3Kδ inhibitor. ....

United States , Mashonaland East , South Africa , Cape Town , Western Cape , Groote Schuur , Deborah Braccia , Ernesto Aycardi , Gary Zieziula , Asia Pacific , Leslie Dennis , Lauren Walrath , Development Officer , Global Medical Affairs , American Medical Affairs , College Of Physicians South Africa , Merck Co , Prnewswire Kyowa Kirin Inc , Critical Path Institute , A Global Specialty Pharmaceutical Company , Public Affairs , Kyowa Kirin Co Ltd , Head Of Global Medical Affairs Excellence , Godfrey Huggins School Of Medicine , Kyowa Kirin Inc , University Of Zimbabwe ,

Kyowa Kirin Announces Positive Phase 2 Results for KHK4083 in Patients with Moderate to Severe Atopic Dermatitis

Press release content from Business Wire. The AP news staff was not involved in its creation.
Kyowa Kirin Announces Positive Phase 2 Results for KHK4083 in Patients with Moderate to Severe Atopic Dermatitis
February 18, 2021 GMT
TOKYO (BUSINESS WIRE) Feb 18, 2021
For Medical Media only. Kyowa Kirin Co., Ltd. (TSE: 4151, President and CEO: Masashi Miyamoto, “Kyowa Kirin”), a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, announces today that the Phase 2 study of investigational agent KHK4083 in patients with atopic dermatitis has met the primary endpoint.
KHK4083 is a potential first-in-class, anti-OX40 fully human monoclonal antibody for the treatment of autoimmune diseases, including atopic dermatitis. KHK4083 was first discovered by Kyowa Kirin, and is produced with the Company’s patented POTELLIGENT ® defucosylation technology to enhance its antibody dependen ....

United States , Masashi Miyamoto , Stacey Minton , Emma Guttman Yassky , Asia Pacific , Tomomasa Yagisawa , Lauren Walrath , Hiroki Nakamura , A Global Specialty Pharmaceutical Company , Kyowa Kirin Group , Icahn School Of Medicine At Mount Sinai , Kyowa Kirin Co Ltd , Department Of Dermatology , Kyowa Kirin International , Medical Media , Kyowa Kirin , Eczema Area , Severity Index , Global Assessment , System Chair , Waldman Professor , Icahn School , Mount Sinai , Inflammatory Skin Diseases , Yoshifumi Torii , Executive Officer ,